Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) research hub

A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL

This study is testing a new medicine called JNJ-75348780 for people with certain types of lymphoma and leukaemia. It's the very first time this medicine is being given to humans, to see if it's safe and how much to give.